D.E. Shaw & Co
CLVS

D.E. Shaw & Co’s Clovis Oncology, Inc. CLVS Stock Holding History

D.E. Shaw & Co’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-44,924
Closed -$53K – 5404
2022
Q3 		$53K Buy
+44,924
New +$70K ﹤0.01% 4683
2022
Q2 		– Sell
-428,506
Closed -$866K – 5976
2022
Q1 		$866K Buy
428,506
+64,120
+18% +$126K ﹤0.01% 4029
2021
Q4 		$987K Buy
364,386
+350,630
+2,549% +$1.3M ﹤0.01% 3935
2021
Q3 		$61K Sell
13,756
-8,487
-38% -$40.9K ﹤0.01% 4797
2021
Q2 		$129K Sell
22,243
-34,157
-61% -$200K ﹤0.01% 4519
2021
Q1 		$396K Buy
+56,400
New +$378K ﹤0.01% 3607
2020
Q4 		– Sell
-14,677
Closed -$86K – 4236
2020
Q3 		$86K Buy
+14,677
New +$87.8K ﹤0.01% 3722
2020
Q2 		– Sell
-36,567
Closed -$233K – 4322
2020
Q1 		$233K Sell
36,567
-389,964
-91% -$3.13M ﹤0.01% 3585
2019
Q4 		$4.45M Sell
426,531
-1,335,983
-76% -$9.71M 0.01% 1822
2019
Q3 		$6.93M Buy
1,762,514
+812,902
+86% +$6.58M 0.01% 1415
2019
Q2 		$14.1M Buy
949,612
+494,733
+109% +$8.94M 0.02% 947
2019
Q1 		$11.3M Buy
454,879
+443,569
+3,922% +$11.1M 0.01% 1033
2018
Q4 		$203K Sell
11,310
-225,640
-95% -$4.61M ﹤0.01% 3541
2018
Q3 		$6.96M Buy
236,950
+68,392
+41% +$2.65M 0.01% 1339
2018
Q2 		$7.66M Sell
168,558
-150,472
-47% -$7.32M 0.01% 1244
2018
Q1 		$16.8M Buy
319,030
+76,646
+32% +$4.47M 0.02% 745
2017
Q4 		$16.5M Buy
242,384
+39,972
+20% +$2.79M 0.02% 771
2017
Q3 		$16.7M Sell
202,412
-877,319
-81% -$69.6M 0.03% 692
2017
Q2 		$101M Sell
1,079,731
-554,741
-34% -$33.9M 0.17% 139
2017
Q1 		$104M Buy
1,634,472
+922,235
+129% +$56.1M 0.18% 120
2016
Q4 		$31.6M Buy
712,237
+309,288
+77% +$10.9M 0.05% 450
2016
Q3 		$14.5M Sell
402,949
-190,532
-32% -$4.09M 0.03% 709
2016
Q2 		$8.14M Sell
593,481
-485,440
-45% -$7.1M 0.02% 1004
2016
Q1 		$20.7M Buy
1,078,921
+135,402
+14% +$2.87M 0.04% 527
2015
Q4 		$33M Buy
943,519
+596,215
+172% +$38.5M 0.05% 429
2015
Q3 		$31.9M Buy
347,304
+155,736
+81% +$13.5M 0.05% 442
2015
Q2 		$16.8M Buy
191,568
+24,210
+14% +$2.07M 0.03% 702
2015
Q1 		$12.4M Sell
167,358
-1,791
-1% -$126K 0.02% 838
2014
Q4 		$9.47M Sell
169,149
-7,319
-4% -$385K 0.01% 1147
2014
Q3 		$8.01M Sell
176,468
-182,521
-51% -$7.62M 0.01% 1231
2014
Q2 		$14.9M Sell
358,989
-160,396
-31% -$8.26M 0.02% 853
2014
Q1 		$36M Sell
519,385
-82,028
-14% -$6.02M 0.05% 401
2013
Q4 		$36.2M Sell
601,413
-68,892
-10% -$3.75M 0.05% 416
2013
Q3 		$40.7M Buy
670,305
+267,104
+66% +$18.9M 0.07% 326
2013
Q2 		$27M Buy
+403,201
New +$18.1M 0.05% 412

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

D.E. Shaw & Co's CLVS Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 44,924 shares — an estimated $53K sold.

D.E. Shaw & Co first reported a position in CLVS in Q2 2013 and held it in 35 quarters. The position peaked at $104M in Q1 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • D.E. Shaw & Co reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 44,924 Clovis Oncology, Inc. shares in Q4 2022, an estimated $53K.
  • D.E. Shaw & Co first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 35 quarters.
  • D.E. Shaw & Co's Clovis Oncology, Inc. position peaked at $104M in Q1 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.